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Uncomplicated urinary tract infections (UTIs) are usually diagnosed 
in previously healthy women with no underlying disease or 
anatomical anomalies, whereas complicated UTIs refer to patients 
with co-morbidities, anatomical anomalies, and catheter-associated 
or nosocomially acquired infections.1 UTIs are a global financial 
burden, and the emergence of resistance in uncomplicated and 
complicated uropathogens is of great concern.2
Escherichia coli (E. coli) is the most common uropathogen in both 
uncomplicated and complicated UTIs.1 There is a wide spectrum 
of pathogens causing complicated UTIs including E. coli, Klebsiella, 
Pseudomonas, Enterobacter, Enterococcus and Candida species.1,3
Guidelines recommend a short course of trimethoprim-
sulfamethoxazole (TMP-SMX) for the empiric treatment of 
uncomplicated UTIs if resistance is less than 20%.5-7 In South Africa, 
TMP-SMX is widely used for UTI prophylaxis and treatment, 
and for Pneumocystis jirovecii prophylaxis in immunocompromised 
patients, which has led to increased bacterial resistance.8 In a setting 
where more than 20% of E. coli cultures are resistant to TMP-SMX, 
guidelines recommend ciprofloxacin, nitrofurantoin or fosfomycin.6 
Kallen et al. were concerned about the increased use of quinolones 
causing increased resistance to this class of antibiotics.9 Worldwide 
changes in susceptibility of E. coli have occured, and the prevalence 
of community-acquired extended-spectrum beta-lactamase (ESBL) 
producing organisms has increased.10-12
Surveillance data must be regularly collected for a specific infection 
to guide antibiotic use.3 Prior antibiotic exposure must be kept in 
mind when deciding on empiric antibiotics as this is a strong risk 
factor for resistant E. coli UTIs.13
Methods
A retrospective survey of antimicrobial susceptibility data and 
antibiotic prescribing behaviour for adult (>12 years old) outpatient 
UTIs at 3 Military Hospital, Bloemfontein, was done.
Resistance patterns may differ depending on the geographic 
area, and have not previously been documented for UTIs in this 
institution. Our objectives were to identify the aetiological agents 
associated with uncomplicated and complicated UTIs, and the rate of 
resistance, and design appropriate empiric evidence-based antibiotic 
guidelines for this institution.
Permission for the study was granted by the Hospital Administrator 
and the Ethics Committee of the Faculty of Health Sciences, University 
of the Free State.
Members and retired members and their families of the South 
African National Defence Force (SANDF) are seen exclusively by 
military-appointed doctors, and medication dispensed by military 
pharmacies. All encounters are captured in an electronic database. A 
list of all urine samples sent from 3 Military Hospital from January to 
December 2008 was compiled from the DISA system by the National 
Health Laboratory Service (NHLS).
Positive urine cultures collected from the casualty, gynaecology, 
internal medicine and surgical outpatient departments were included. 
If more than one urine microscopy, culture and sensitivity (MC&S) 
specimen was sent during a specific UTI episode, only the first 
specimen was included. 
Electronic database and paper-based patient records were used to 
compile a list of co-morbidities, antibiotic use during the previous year, 
and antibiotics prescribed for the UTI episode under investigation.
Uncomplicated UTIs were defined as the first episode of UTI 
in outpatients with no underlying anatomical anomalies and no 
indwelling devices. For this study, the first UTI in pregnant women 
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and in diabetic patients was regarded as uncomplicated. Patients with 
complicated UTIs were defined as: males (including BPH, prostatitis, 
epididymo-orchitis, prostate cancer), following a recent cystoscopy, 
with indwelling urinary catheters/intermittent self-catheterisation, 
recurrent UTIs in females (defined as ≥3 culture-positive UTIs per 
year), urological abnormalities, pyelonephritis, renal failure, renal 
stones, UTIs with multiple organisms, and UTIs in patients who were 
recently  hospitalised.
Cultures positive for Candida species and cultures with mixed 
growth were excluded. Mixed growth was defined as a growth of 
more than one organism in a midstream urine sample indicative 
of contamination. If it was a sterile urine sample (e.g. supra-pubic 
catheter sample), multiple organisms were reported as pathogenic.
Results
Fig. 1 illustrates the selection process used to isolate the first positive 
culture per patient (N=65) from the 791 samples sent for MCS during 
2008. These samples were divided into uncomplicated (N=28) and 
complicated (N=37) UTIs.
In the complicated group, 54% (N=20) were female and 46% 
(N=17) male. The age distribution for both groups is illustrated in 
Fig. 2. No growth was recorded in 66 % of samples (N=525). Sixty-
eight samples had mixed growth.
Uncomplicated UTIs
E. coli was responsible for 75% (N=21), Enterococcus faecalis (E. 
faecalis), Proteus mirabilis and Streptococcus agalactiae for 7% (N=2) 
each, and Klebsiella pneumoniae for one episode of uncomplicated 
UTI in this population. There were no cases of extended spectrum 
β-lactamase (ESBL) producing organisms. 
For E. coli isolates only
Further analysis of the E. coli isolates (N=21) showed sensitivity to 
nitrofurantoin and cefuroxime in all 21 cultured cases. Amoxicillin 
and TMP-SMX had the highest resistance rate (57%, N=12 and 52%, 
N=11 respectively), followed by ciprofloxacin and co-amoxiclav 
with 5% (N=1) each. One sample had only intermediate sensitivity 
to co-amoxiclav (Fig. 3). Co-amoxiclav was the most frequently 
prescribed antibiotic (38%, N=8), followed by ciprofloxacin 
(19%, N=4), amoxicillin (14%, N=3), cefuroxime (10%, N=2) and 
nitrofurantoin (5%, N=1). TMP-SMX was never prescribed, and 3 
patients did not have any record of antibiotics dispensed.
For all uncomplicated UTIs
Analysis of all uncomplicated UTIs (N=28) showed resistance 
to co-amoxiclav in only 4% (N=1). TMP-SMX and amoxicillin 
had the highest resistance rates of 54% (N=15) and 46% (N=13) 
respectively, followed by cefuroxime 14% (N=4) and ciprofloxacin 
and nitrofurantoin with 11% (N=3) resistance (Fig. 4). Co-amoxiclav 
was the most frequently prescribed antibiotic (36%, N=10), followed 
by ciprofloxacin (18%, N=5), amoxicillin (11%, N=3), cefuroxime 
and TMP-SMX (7% each, N=2) and nitrofurantoin (4%, N=1). One 
patient received azithromycin, and 4 patients did not receive any 
Fig. 1. Selection process used to determine isolated outpatient urinary tract 
infections (UTIs).
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Fig. 2. Age distribution of patients.
Fig2 
The bottom and right hand side of this figure was cut off. Here is the complete figure. 
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antibiotics. Treatment durations were in most cases significantly 
longer than the recommended 3-day course: 5 days (46%), 7 days 
(7%), and 10 days (7%).
The prescribed antibiotic was appropriate in 75% of all 
uncomplicated UTIs according to the antibiogram.
Of females with uncomplicated UTIs, 25% were older than 65 years 
and 39% (N=11) were pregnant. Samples were mostly sent during 
the first trimester (N=8). Concomitant problems included:  diabetes 
mellitus (N=3), HIV-positive (N=4), breast cancer (N=1), cervical 
intraepithelial neoplasia (CIN) lesion (N=1), Alzheimer’s disease 
(N=1), recent episode of vaginitis (N=2), intra-uterine device (N=2) 
and incompetent cervix (N=1).
Fifty-four per cent (N=15) of patients had had recent antibiotic 
exposure unrelated to UTIs. 
Complications following uncomplicated UTIs were late 
re-infections (N=3), one Citrobacter freundii and 2 E. coli urinary 
tract infections. One of these patients had 2 positive urinary cultures 
with an ESBL-producing E. coli and E. faecalis infection within the 
following 2 months. Two patients cultured a different organism in the 
next 7 - 10 days after their first positive urine culture.
Complicated UTIs
For complicated UTIs, E. coli was responsible for 59% (N=22), 
Enterococcus cloacae, E. faecalis and K. pneumoniae 8% each (N=3) 
and Streptococcus agalactiae for 5% (N=2) of UTIs. Each of the 
following was responsible for one episode: Acinetobacter baumanii, 
Citrobacter freundii, coagulase negative staphylococcus, Enterococcus 
spp, Morganella morganii, Pseudomonas aeruginosa, Proteus mirabilis, 
Streptococcus spp, Staphylococcus epidermidis, Staphylococcus 
haemolyticus and Staphylococcus saprophyticus.
Two E. cloacae and one E. coli isolates were ESBL producers.
A single organism was isolated in 84% of complicated UTIs 
(N=31). Five of the remaining urine samples cultured 2 organisms, 
and 1 urine sample cultured 3 organisms.
For E. coli isolates only
Analysis of the antibiograms of the E. coli isolates (N=22) showed 
that nitrofurantoin had a 100% sensitivity rate. TMP-SMX and 
amoxicillin had the highest resistance rates (82%, N=18 and 73%, N=16 
respectively), followed by ciprofloxacin (45%, N=10), and cefuroxime 
and co-amoxiclav with 9% (N=2) each (Fig. 5). Ciprofloxacin was 
the most frequently prescribed antibiotic (29%, N=6), followed by 
nitrofurantoin and co-amoxiclav (14%, N=3), amoxicillin and TMP-
SMX both at 10% (N=2), and cefuroxime at 5% (N=1). Twenty-nine 
per cent (N=6) of the patients did not receive any antibiotics.
For all complicated UTIs
Of all complicated UTIs (N=37), nitrofurantoin was the agent with 
the lowest resistance rate of 22% (N=8). Two cultured organisms 
were only intermediately sensitive to nitrofurantoin. TMP-SMX 
and amoxicillin had the highest resistance rate (68%, N=25 and 
65%, N=24, respectively), followed by cefuroxime and ciprofloxacin 
at 41% (N=15) each and co-amoxiclav at 27% (N=10) (Fig. 6). 
Ciprofloxacin was the most frequently prescribed antibiotic (35%, 
N=13), followed by co-amoxiclav (19%, N=7), TMP-SMX, amoxicillin 
and nitrofurantoin (11%, N=4) each, and cefuroxime at 8% (N=3). No 
antibiotics were prescribed in 24% of cases. Treatment durations were 
as follows: 1 - 3 days (5%), 5 days (24%), 7 days (5%), 10 days (19%) 
and not specified (22%).
The empiric choice of antibiotics was appropriate in 46% (N=17) 
of all complicated UTIs.
Concomitant problems included: diabetes mellitus (N=9), 
malignancies (N=5), recurrent UTI during pregnancy (N=3), 
HIV-positive (N=3), epididymo-orchitis (N=2), benign prostate 
hypertrophy (N=2), prostatitis (N=2), prostate cancer (N=2), 
procedure-related (N=2), urinary catheter-associated (N=9), recurrent 
infections in females (N=4), renal failure (N=4), renal stones (N=1), 
urological abnormalities (N=6) and pyelonephritis (N=2). One 
patient had had a previous UTI with a resistant organism.
Sixty-two per cent (N=23) of the patients had antibiotic exposure 
in the previous year, and 19% (N=7) had been admitted during the 
previous year; 13 had recurrent/late re-infections, including one 
ESBL-producing E. coli and one ESBL-producing E. cloacae.
Discussion
The causative organisms and resistance patterns in a given population 
for a specific infection must be audited to guide the empirical use of 
antibiotics. Antibiotic choices are determined by in vitro susceptibility, 
adverse effects, cost, efficacy and selection pressure to limit resistant 
strains. With more than 20% of cultured organisms resistant to TMP-
SMX and amoxicillin in uncomplicated and complicated UTIs, these 
two antibiotics cannot be used empirically in this setting.
Nitrofurantoin is an effective urinary tract antiseptic that is not 
used for other kinds of infection. It does not affect antibiotic use in 
any other infection, and it has a resistance rate of less than 20% in 
this study. Therefore it should be used as first-choice treatment in 
uncomplicated UTIs in this hospital.
Ciprofloxacin was the most used antibiotic in complicated UTIs 
and the second-most used antibiotic in uncomplicated UTIs. 
Ciprofloxacin had resistance rates of 11% in uncomplicated and 41% 
in complicated UTIs. Quinolones as a class induce resistance against 
a wide spectrum of unrelated antibiotics. Overuse of quinolones also 
Fig. 5. Resistance to antibiotics in complicated UTIs for E. coli isolates only 
(N=22).
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increases the incidence of methicillin-resistant S. aureus (MRSA) 
in hospital and community settings.14 It is also the most potent 
antibiotic in the second-line treatment of tuberculosis. With the high 
rates of tuberculosis in South Africa, inappropriate use will have far-
reaching consequences. We strongly advise against the empiric use 
of quinolones.
Our study revealed high rates of prior antibiotic use for UTIs and 
other unrelated infections such as upper respiratory tract infections. 
These prior antibiotics might have played a role in the current 
resistance profiles. Since this is a retrospective study, patients could 
have had more previous antibiotic exposure than documented. 
A meta-analysis showed that antibiotic use in primary care for 
respiratory or urinary infections leads to selection of resistance to that 
antibiotic, and that this would lead to increased population carriage 
of resistant organisms and increased use of second-line antibiotics.15 
It was also reported that infection with organisms with resistance 
after prior antibiotic use was greatest in the month immediately after 
treatment, but could persist for up to 12 months.15
Evidence-based choices of antibiotics should be practised. The 
result will be less resistance, fewer re-consultations, cost savings and 
less patient morbidity and mortality.16
A very high rate of culture-negative urine samples was received 
at the laboratory. This might imply that samples are sent for culture 
inappropriately. Routine urine culture is not necessary.4 Cost savings 
can be effected by sending samples from patients only with both 
symptoms of UTI and an abnormality on urine dipstick. The dipstick 
strategy is most likely to be cost-effective.17 These criteria will also 
help to limit the unnecessary use of empiric antibiotics.
TMP-SMX and amoxicillin are of no use in this population with 
UTIs. Nitrofurantoin should be the empiric choice for uncomplicated 
UTIs.
More than 20% of cultured bacteria in complicated UTIs were 
resistant to ciprofloxacin, which is commonly empirically prescribed. 
In this setting, ciprofloxacin should not be used empirically for 
complicated UTIs. For complicated UTIs, prior antibiotic use and 
expert clinical opinion should guide the empiric use of antibiotics 
while culture and sensitivity results are awaited.
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